Your session is about to expire
← Back to Search
Behavioural Intervention
Atomic App for Pediatric Cancer Survivors
N/A
Recruiting
Led By Olga H Toro-Salazar
Research Sponsored by Connecticut Children's Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial tested an app to increase exercise in childhood cancer survivors, to improve their health. #physicalactivity #childhoodcancer
Who is the study for?
This trial is for childhood cancer survivors aged 10 to 30 who can speak English fluently. They must have been treated with anthracycline therapy. It's not suitable for those unable to cooperate in interviews, non-English speakers, or anyone unable to understand interview content.
What is being tested?
The ATOMIC mobile app is being tested for its ability to increase physical activity levels among children and young adults who survived pediatric cancer. The study involves development and usability testing of the app specifically designed for this group.
What are the potential side effects?
Since this trial tests a mobile app designed to encourage physical activity, there are no direct medical side effects like you'd expect from medication. However, participants may experience fatigue or muscle soreness typical with new exercise routines.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Ease of use and user errors will be documented for each individual during usability testing, by completing several tasks while navigating the mobile app platform
The Acceptability E-Scale is six-item tool that has been validated for assessing the usability, acceptability, and satisfaction of web based programs with statements ranked on a five point scale from very difficult to very easy
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Real life usability testingExperimental Treatment1 Intervention
B) "Real Life" Usability Testing. We will conduct a "real life" usability test in a sample of 6 pediatric cancer survivors. EX@HOME: Patients will perform an individualized aerobic and resistance exercise intervention, choosing from a list of PA, progressing from light to moderate-to-vigorous intensity totaling 30-45 min/d, 4-5 weekly/wk. for 4 weeks. The social-cognitive-theory-based mobile app will support the exercise intervention. One-on-one messaging chats with a PA coach through the mobile app will facilitate exercise goal establishment and attainment.
Find a Location
Who is running the clinical trial?
Connecticut Children's Medical CenterLead Sponsor
73 Previous Clinical Trials
26,560 Total Patients Enrolled
The Hospital for Sick ChildrenOTHER
712 Previous Clinical Trials
6,959,703 Total Patients Enrolled
Olga H Toro-SalazarPrincipal InvestigatorCT Children's Medical Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not speak English.I am between 10 and 30 years old.I am a child cancer survivor not scheduled for anthracycline therapy.I am unable to participate in interviews.I can speak English fluently.My child's cancer treatment includes anthracycline therapy.
Research Study Groups:
This trial has the following groups:- Group 1: Real life usability testing
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.